Dazukibart
Pfizer
['derm']
a monoclonal antibody targeting ifn-beta provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase 2 trial. #aad2023 #dermtwitter 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.